Cloning

ViaCyte to Present at the Jefferies Virtual Healthcare Conference

Thursday, May 28, 2020 - 2:00pm

SAN DIEGO, May 28, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9.

Key Points: 
  • SAN DIEGO, May 28, 2020 /PRNewswire/ -- ViaCyte, Inc. , a privately held regenerative medicine company, announced today that ViaCyte's President and CEO Paul Laikind, Ph.D. is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10 a.m. Eastern Time in Track 9.
  • ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement.
  • During the presentation, Dr. Laikind will discuss ViaCyte's leadership in discovering and developing novel cell replacement therapies to treat human diseases.
  • With CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 pluripotent stem cell line.

Insights into North America's Biobanks Market 2020, Featuring Key Player Profiles Including Atlanta Biologicals Inc., BioLifeSolutions Inc. and Thermo Fisher Scientific Inc.

Friday, May 22, 2020 - 10:15pm

Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.

Key Points: 
  • Stem cell practices are on the rise and are contributing to the development of new solutions for various diseases.
  • Several advancements have been made in regenerative medicine through stem cell technology over the past decade.
  • Thus, it has become one of the vital treatment methods for diseases, such as Alzheimer's, diabetes, cancer, and rare genetic diseases.
  • In order to benefit from the existing therapies, umbilical cord cells and other stem cells are preserved in Biobanks.

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's disease treatment

Friday, May 22, 2020 - 3:29am

HONG KONG, May 22, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.

Key Points: 
  • HONG KONG, May 22, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.
  • They found that the transplantation of these nerve cells into rats with Parkinson's disease progressively improved their symptoms, with the new cells replacing damaged nerve cells around the transplantation site.
  • This novel invention provides promising insights into stem cell therapies and offers hope of a new treatment for Parkinson's disease.
  • The chemicals used may stimulate the growth of cancer cells and increase the risk of developing tumours after transplantation to human body.

HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's disease treatment

Friday, May 22, 2020 - 3:24am

HONG KONG, May 21, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.

Key Points: 
  • HONG KONG, May 21, 2020 /PRNewswire/ -- Researchers from Hong Kong Baptist University (HKBU) have invented a nanostructure that can stimulate neural stem cells to differentiate into nerve cells.
  • They found that the transplantation of these nerve cells into rats with Parkinson's disease progressively improved their symptoms, with the new cells replacing damaged nerve cells around the transplantation site.
  • This novel invention provides promising insights into stem cell therapies and offers hope of a new treatment for Parkinson's disease.
  • The chemicals used may stimulate the growth of cancer cells and increase the risk of developing tumours after transplantation to human body.

eGenesis Strengthens Production Capabilities with Acquisition of ICBiotec

Wednesday, May 20, 2020 - 1:00pm

ICB is one of the few companies in the U.S. with advanced cloning and large animal transgenic production capabilities integral to the xenotransplantation supply chain.

Key Points: 
  • ICB is one of the few companies in the U.S. with advanced cloning and large animal transgenic production capabilities integral to the xenotransplantation supply chain.
  • The acquisition will provide eGenesis with full control of its xeno-organ supply chain.
  • eGenesis is committed to advancing therapies for patients in need of organ, tissue, and cell transplants, said Paul Sekhri, President and Chief Executive Officer of eGenesis.
  • The acquisition of ICB is a key part of our strategic development plan and enables us to vertically integrate our research, cloning, and production capabilities.

Meso Numismatics Provides Update On Global Stem Cell Transaction

Tuesday, May 19, 2020 - 12:55pm

LAS VEGAS, NV, May 19, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that the Company has successfully made its first $50,000 payment to Global Stem Cells Group (GSCG), as per the Companys updated LOI amendment, dated April 22nd, 2020, to complete its acquisition of the stem cell operation.

Key Points: 
  • LAS VEGAS, NV, May 19, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that the Company has successfully made its first $50,000 payment to Global Stem Cells Group (GSCG), as per the Companys updated LOI amendment, dated April 22nd, 2020, to complete its acquisition of the stem cell operation.
  • We look forward to completing the acquisition of Global Stem Cells Group, stated David Christensen, President of MSSV.
  • We are very optimistic about the opportunities that stem cell technology can offer to the world and confident that Global Stem Cells Group has the ability to help facilitate these therapies on a large scale.
  • Meso Numismatics is a numismatic company specializing in the Meso Region, including Central America and the Caribbean.

R3 Stem Cell International Now Offering Enhanced Autism Stem Cell Program in Mexico

Monday, May 18, 2020 - 5:00am

SCOTTSDALE, Ariz., May 18, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell International is now offering an enhanced autism stem cell therapy program at its Tijuana regenerative clinic.

Key Points: 
  • SCOTTSDALE, Ariz., May 18, 2020 /PRNewswire-PRWeb/ -- R3 Stem Cell International is now offering an enhanced autism stem cell therapy program at its Tijuana regenerative clinic.
  • R3 Stem Cell International's enhanced program provides umbilical cord derived stem cell therapy for patients, with total cell counts for the treatment ranging between 90 million up to 200 million live stem cells.
  • As with all R3 Stem Cell International procedures, R3 takes care of concierge escort transportation from San Diego to the clinic, which is only 20 minutes from the SD International Airport.
  • About R3 Stem Cell International: After 14,000 stem cell procedures in the US, R3 opened R3 Stem Cell International.

Novel Treatment Using Patient's Own Cells Opens New Possibilities to Treat Parkinson's Disease

Wednesday, May 13, 2020 - 11:11pm

The progressive loss of brain cells called dopaminergic neurons plays a major role in the disease's development.

Key Points: 
  • The progressive loss of brain cells called dopaminergic neurons plays a major role in the disease's development.
  • "Because the cells come from the patient, they are readily available and can be reprogrammed in such a way that they are not rejected on implantation.
  • The McLean-MGH team reprogrammed a 69-year-old patient's skin cells to embryo-like pluripotent stem cells (called induced pluripotent stem cells) and then differentiated them to take on the characteristics of dopaminergic neurons, which are lost in Parkinson's.
  • While there is optimism about the future of Parkinson's disease treatments because of their work, Schweitzer cautions against declaring victory against the disease.

AgeX Therapeutics Announces Reduction in Projected Cash Expenditures

Friday, May 1, 2020 - 1:54pm

AgeX plans to continue to pursue its licensing and collaboration strategy for its two primary technology platforms, UniverCyte immunotolerance technology, and PureStem cell derivation and manufacturing technology.

Key Points: 
  • AgeX plans to continue to pursue its licensing and collaboration strategy for its two primary technology platforms, UniverCyte immunotolerance technology, and PureStem cell derivation and manufacturing technology.
  • Development of AgeXs iTR technology may be done at AgeXs subsidiary Reverse Bioengineering, Inc. subject to successful financing of the subsidiary.
  • AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.
  • AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

Genedata Partners with Cergentis to Provide End-to-end Solution for Automating TLA-based Clone Selection

Tuesday, April 28, 2020 - 1:30pm

The cutting-edge TLA technology is used during cell line development to standardize and speed up the clone selection process.

Key Points: 
  • The cutting-edge TLA technology is used during cell line development to standardize and speed up the clone selection process.
  • This information is highly relevant to quickly assess the quality of cell line clones during cell line development.
  • With Genedata Selector we now provide a solution that fully supports the deployment of their TLA technology," said Othmar Pfannes, Ph.D., Founder and CEO of Genedata.
  • Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.